Article

Positive Results Seen in Ibrance Breast Cancer Trial

Pfizer announced Ibrance met its primary endpoint in postmenopausal women with human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer.

Pfizer recently announced promising results from a phase 3 trial for palbociclib (Ibrance) as a first-line treatment for a specific group of breast cancer patients.

PALOMA-2 is a randomized (2:1), multicenter, multinational, double-blind phase 3 study.

Progression free survival (PFS) was evaluated in 666 postmenopausal women with human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer.

Patients enrolled in the trial had not received previous systemic treatment.

Patients were randomized to receive a combination therapy of Ibrance (125-mg daily for 3 of 4 weeks in repeated cycles) and letrozole (2.5 mg once daily) or letrozole plus placebo as a first-line treatment.

Researchers found that patients receiving the combination of Ibrance and letrozole showed an improvement in PFS compared with patients receiving letrozole and a placebo.

Adverse events experienced with Ibrance and letrozole were said to be consistent with its safety profile.

Ibrance is first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6.

The drug was initially approved in February 2016 for hormone receptor-positive, HER2-advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy.

“PALOMA-2 represents the third randomized study to demonstrate the benefit of Ibrance when added to hormonal therapy in the management of women with ER+, HER2- advanced breast cancer. Ibrance remains the only CDK 4/6 inhibitor with Phase 3 data in this disease,” said Mace Rothenberg, MD, chief medical officer, Pfizer Oncology and senior vice president, Global Product Development, Oncology. “These results provide confirmatory evidence for PALOMA-1 and will be used to support regulatory submissions around the world, including a request for conversion of Ibrance from accelerated to full approval in the United States. We look forward to sharing the detailed results of PALOMA-2 with the oncology community and advancing our discussions with regulatory authorities.”

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com